InflaRx N.V. (IFRX)

NASDAQ: IFRX · IEX Real-Time Price · USD
1.538
-0.002 (-0.13%)
Mar 28, 2024, 1:35 PM EDT - Market open

Company Description

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States.

The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases.

Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage.

The company also develops INF904, an oral, small molecule drug candidate for the chronic inflammatory and autoimmune diseases; and IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases.

It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. The company was formerly known as Fireman B.V.

and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.

InflaRx N.V.
InflaRx logo
Country Germany
Founded 2007
IPO Date Nov 8, 2017
Industry Biotechnology
Sector Healthcare
Employees 62
CEO Dr. Niels C. Riedemann M.D., Ph.D.

Contact Details

Address:
Winzerlaer Str. 2
Jena, 2M 07745
Germany
Phone 49 3641 508180
Website inflarx.de

Stock Details

Ticker Symbol IFRX
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001708688
CUSIP Number N44821101
ISIN Number NL0012661870
SIC Code 2834

Key Executives

Name Position
Dr. Niels C. Riedemann M.D., Ph.D. Co-Founder, Chief Executive Officer and Executive Director
Prof. Renfeng Guo M.D. Co-Founder, Chief Scientific Officer and Executive Director
Dr. Thomas Taapken Ph.D. Chief Financial Officer
Derval O'Carroll Senior Vice President and Global Head of Regulatory Affairs and Compliance
Dr. Camilla Chong M.D. Chief Medical Officer
Jan Medina CFA Head of Investor Relations and Vice President
Christian Schmid Vice President and Head of Legal Affairs and General Counsel
Nicole Bertsch Senior Director and Head of Human Resources
Dr. Maria Habel PH.D. Vice President, Head of Preclinical Research & Development and QC
Dr. Bruce P. Burnett Ph.D. Vice President and Head of Medical Affairs

Latest SEC Filings

Date Type Title
Mar 21, 2024 6-K Report of foreign issuer
Mar 21, 2024 20-F Annual and transition report of foreign private issuers
Mar 21, 2024 6-K Report of foreign issuer
Feb 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Jan 25, 2024 6-K Report of foreign issuer
Jan 4, 2024 6-K Report of foreign issuer
Nov 6, 2023 6-K Report of foreign issuer
Nov 1, 2023 6-K Report of foreign issuer
Sep 11, 2023 6-K Report of foreign issuer
Aug 30, 2023 6-K Report of foreign issuer